Cart
sales@molnova.com
Piflufolastat
CAS No. 1423758-00-2
Piflufolastat( —— )
Catalog No. M34569 CAS No. 1423758-00-2
Piflufolastat (DCFPYL) is a PET imaging agent for prostate cancer PSMA. It is a fluorinated prostate-specific membrane antigen (PSMA) preparation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 141 | In Stock |
|
| 5MG | 117 | In Stock |
|
| 10MG | 188 | In Stock |
|
| 25MG | 432 | In Stock |
|
| 50MG | 732 | In Stock |
|
| 100MG | 1265 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePiflufolastat
-
NoteResearch use only, not for human use.
-
Brief DescriptionPiflufolastat (DCFPYL) is a PET imaging agent for prostate cancer PSMA. It is a fluorinated prostate-specific membrane antigen (PSMA) preparation.
-
DescriptionPiflufolastat (DCFPYL) can be used to the preparation of piflufolastat F 18 (DCFPyL F-18). piflufolastat F 18. Piflufolastat F-18 is an 18F-labelled diagnostic imaging agent. Piflufolastat F-18 can be used for positron emission tomography (PET) that targets prostate-specific membrane antigen (PSMA).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain | PSMA
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1423758-00-2
-
Formula Weight442.4
-
Molecular FormulaC18H23FN4O8
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(NCCCC[C@H](NC(N[C@@H](CCC(O)=O)C(O)=O)=O)C(O)=O)(=O)C=1C=CC(F)=NC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Keam SJ, et al. Piflufolastat F 18: Diagnostic First Approval. Mol Diagn Ther. 2021 Sep;25(5):647-656. ?
molnova catalog
related products
-
GSK620
GSK620 is a pan-BD2 inhibitor, which shows an anti-inflammatory phenotype in human whole blood with excellent broad selectivity, developability, and in vivo oral pharmacokinetics.
-
BRD4-BD1-IN-2
BRD4-BD1-IN-2 is a selective and potent BRD4-BD1 inhibitor with an IC50 value of 2.51 μM, exhibiting 20-fold greater inhibitory activity against BRD4-BD1 compared to BRD4-BD2.
-
dCBP-1
dCBP-1 is a chemical degrader of p300/CBP. dCBP-1 hijacks the E3 ubiquitin ligase CRBN for selective degradation of p300/CBP. Degradation of p300/CBP by dCBP-1 leads to effective multiple myeloma cell killing.
